Pathogen-Reduced Platelet Concentrates: Experience in Routine Practice in Germany

Inclusion Criteria: * Patients ≥ 18 years * Patients who, based on clinical indications\*, receive at least one platelet transfusion with a pathogen-reduced platelet concentrate for treatment of bleeding risk caused by severe thrombocytopenia resulting from impaired platelet production. (\* Taking into account the Cross-sectional Guidelines on the transfusion of blood components and plasma derivatives issued by the German Medical Association (Bundesärztekammer) in its current version.) Exclusion Criteria: Patients will not be included if they fulfil at least one of the following exclusion criteria: * Known hypersensitivity to amotosalen HCl or psoralens. In this case, platelet concentrates treated with this pathogen inactivation method should not be used. * Known allergies of the recipient to human plasma proteins. * Known immune thrombocytopenia. * Thrombotic microangiopathy (thrombotic thrombocytopenic purpura; haemolytic uremic syn-drome). * Post-transfusion purpura. * Heparin-induced thrombocytopenia. * Congenital platelet function disorders, such as Glanzmann's thrombasthenia or Bernard- Souli-er syndrome